Trending...
- Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs - 134
- UK Financial Ltd Completes One Of The Most Extensive CoinMarketCap Supply Verification Packages For Maya Preferred PRA (MPRA)
- The $5 Million Man Still Begging: Incumbent Jimmy Panetta Hits Up Voters for More Cash Despite Massive War Chest
RALEIGH, N.C., April 16, 2021 /PRNewswire/ -- Contego Medical, Inc., a leading developer of innovative cardiovascular devices, today announced receipt of CE Mark approval for the Neuroguard IEP® 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection (Neuroguard IEP System).
The patented Neuroguard IEP System contains a novel, next-generation nitinol stent, a pre-positioned post-dilation balloon and an integrated microembolic filter with 40 μm pores. The closed cell stent is designed to achieve optimal performance across radial strength, vessel coverage and flexibility, additionally featuring a unique asymmetric hourglass design that is flared at both ends to facilitate wall apposition in tortuous anatomy. The integrated filter is designed to capture both macro- and micro-emboli during the entire procedure. The Neuroguard IEP System is indicated for adult patients with clinically significant carotid artery stenosis requiring stenting.
More on ncarol.com
The Neuroguard IEP System was first evaluated in the PERFORMANCE I clinical trial. The study was conducted in nine European sites and included 67 patients with one year follow-up. The overall success rate was 100% with a stroke and death rate of 0% at 30 days1.
"CE Marking of the Neuroguard IEP System is an important milestone for Contego Medical and allows us to bring the remarkable safety and performance benefits of the Neuroguard stent to patients in Europe," said Ravish Sachar, M.D., CEO and Founder of Contego Medical. "We anticipate launching the product in select countries as well initiating a post-marketing clinical study in the coming months."
Stacy Enxing Seng, Venture Partner, Lightstone Ventures, and Contego Medical Board Chair commented "Receipt of CE Mark approval for the Neuroguard IEP System is a significant achievement for the Contego Medical team and represents a multi-year investment in innovative product development and high-quality clinical research. I believe that the Neuroguard IEP System has the performance and ease of use to become the standard of care in the treatment of carotid artery disease."
More on ncarol.com
About Contego Medical
Contego Medical, Inc. is a medical device company dedicated to the development of novel medical devices for cardiovascular and peripheral vascular procedures. The company's Integrated Embolic Protection (IEP) platform, which combines embolic protection and treatment into one device, is designed to simplify catheter-based procedures and improve patient outcomes.
In the United States, the Neuroguard IEP System is an investigational device, limited by United States law to investigational use.
Neuroguard IEP and the Contego Medical logo are registered trademarks of Contego Medical, Inc. The Neuroguard System is covered by U.S. patents 9,968,472 and 10,932,929 and European patent EP 3,367,967. Additional US and Foreign patents pending.
1 LINC 2020
SOURCE Contego Medical, Inc.
The patented Neuroguard IEP System contains a novel, next-generation nitinol stent, a pre-positioned post-dilation balloon and an integrated microembolic filter with 40 μm pores. The closed cell stent is designed to achieve optimal performance across radial strength, vessel coverage and flexibility, additionally featuring a unique asymmetric hourglass design that is flared at both ends to facilitate wall apposition in tortuous anatomy. The integrated filter is designed to capture both macro- and micro-emboli during the entire procedure. The Neuroguard IEP System is indicated for adult patients with clinically significant carotid artery stenosis requiring stenting.
More on ncarol.com
- Alvear Homes Shares Insights on Building Stronger Neighborhood Connections Across NC & SC
- Warm, Dry Summer Forecast Points to a Stronger Wasp and Yellowjacket Season Across the Pacific Northwest
- Qscription Technologies Appoints Anurag Velekkatt Sunil Kumar to Drive Enterprise Scale
- SafeBets Named Presenting Sponsor of IMCX 2026, Bringing Its No-Deposit Prediction Platform to the Creator Economy's Deal-Making Conference
- A New Pulse for Cardiac Care in Baltimore: St. Elizabeth Rehab & Nursing Welcomes Dr. Hakim Uqdah and Expands Advanced Heart Program
The Neuroguard IEP System was first evaluated in the PERFORMANCE I clinical trial. The study was conducted in nine European sites and included 67 patients with one year follow-up. The overall success rate was 100% with a stroke and death rate of 0% at 30 days1.
"CE Marking of the Neuroguard IEP System is an important milestone for Contego Medical and allows us to bring the remarkable safety and performance benefits of the Neuroguard stent to patients in Europe," said Ravish Sachar, M.D., CEO and Founder of Contego Medical. "We anticipate launching the product in select countries as well initiating a post-marketing clinical study in the coming months."
Stacy Enxing Seng, Venture Partner, Lightstone Ventures, and Contego Medical Board Chair commented "Receipt of CE Mark approval for the Neuroguard IEP System is a significant achievement for the Contego Medical team and represents a multi-year investment in innovative product development and high-quality clinical research. I believe that the Neuroguard IEP System has the performance and ease of use to become the standard of care in the treatment of carotid artery disease."
More on ncarol.com
- Inframark–Slater Joint Venture Selected to Manage Fulton County Wastewater Operations
- Cancun International Airport Reports Strong Start to Summer 2026 Travel Season
- Freedomtech Solutions Launches the World's First Pre‑Installed Agentic AI Server — Instant, Sovereign, Infrastructure‑Native Intelligence
- GitKraken Introduces Code Flow, a Framework for Software Development in the Agentic Era
- RIGHT CARS Announces Landmark African Expansion Through Strategic Collaboration Agreement Across Eight Nations
About Contego Medical
Contego Medical, Inc. is a medical device company dedicated to the development of novel medical devices for cardiovascular and peripheral vascular procedures. The company's Integrated Embolic Protection (IEP) platform, which combines embolic protection and treatment into one device, is designed to simplify catheter-based procedures and improve patient outcomes.
In the United States, the Neuroguard IEP System is an investigational device, limited by United States law to investigational use.
Neuroguard IEP and the Contego Medical logo are registered trademarks of Contego Medical, Inc. The Neuroguard System is covered by U.S. patents 9,968,472 and 10,932,929 and European patent EP 3,367,967. Additional US and Foreign patents pending.
1 LINC 2020
SOURCE Contego Medical, Inc.
Filed Under: Business
0 Comments
Latest on ncarol.com
- Embracing Tranquility and Serenity
- CCHR Condemns Behavioral Treatment After FDA's Missed Deadline to Ban Shock Device
- Brilliant Minds to Gather in Fort Worth for National Mensa Event
- Drivin N Cryin at 40: A Spit Shine that Sparkles Differently | Visulite | June 12, 2026 | by Derek Farley
- UK Financial Ltd Completes One Of The Most Extensive CoinMarketCap Supply Verification Packages For Maya Preferred PRA (MPRA)
- A Healthier Home Publishes New EnviroVention™ E-Book
- Data Tiles Strengthens U.S. Presence with Chief Revenue Officer John Goode
- Haven Media Solutions Offers Web Design and PPC Services in Atlanta GA
- New Children's Book Celebrates the Limb Difference Community
- TREND Network Announces Miami Based Reality Series "Coming Up Miami" Premiering July 1
- High Point Girl Scout Troop Helps Transform Community Garden at Senior Living Community
- Beemok Hospitality Collection And KLH Group Announce Preferred Partnership
- Expanding Access to Mental Health Care in Toronto with Dr. Stephen Shainbart
- Dr. Stephen Shainbart Launches Expanded Mental Health Support for Anxiety and Depression in Toronto
- Equipment Leases, Inc. Launches Updated Family Office Equipment Financing Page
- Tickets now available for October 3rd Awadagin Pratt concert at the Tryon Fine Arts Center
- The $5 Million Man Still Begging: Incumbent Jimmy Panetta Hits Up Voters for More Cash Despite Massive War Chest
- Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs
- New from Regal House Publishing, Shout at the Thunder, a girl reveals secrets in a forgotten mansion
- $150+ Million Contracted Backlog, Strategic Acquisitions Adding Millions In Recurring Revenue, Improving Margins & A Clear Path Toward Profitability